Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms

Schizophrenia Research

Volumn 134, Issue 2-3, 2012, Pages 219-225

  Takeuchi, Hiroyoshi ^a   Suzuki, Takefumi ^a   Uchida, Hiroyuki ^a,b   Watanabe, Koichiro ^a   Mimura, Masaru ^a  

^a KEIO UNIVERSITY   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Algorithms; Antipsychotics; Dose; Guidelines; Maintenance; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

CLINICAL PROTOCOL; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; HUMAN; MAINTENANCE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; DATABASES, BIBLIOGRAPHIC; GUIDELINES AS TOPIC; HUMANS; SCHIZOPHRENIA;

EID: 84856243720     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.11.021     Document Type: Review

References (55)

1. Argo T.R., Crismon M.L., Miller A.L., Moore T.A., Bendele S.D., Suehs B. Texas Medication Algorithm Project Procedural Manual, Schizophrenia Treatment Algorithms http://www.dshs.state.tx.us/mhprograms/pdf/SchizophreniaManual_060608.pdf.
2. Barnes T.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2011, 25:567-620. the Schizophrenia Consensus Group of the British Association for Psychopharmacology.
3. Bhanji N.H., Tempier R. Managing schizophrenia during the stable phase: is there consensus among practice guidelines?. Can. J. Psychiatry 2002, 47:76-80.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
5. Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia. Can. J. Psychiatry 2005, 50(Suppl. 1):7S-57S.
6. Carpenter W.T., Buchanan R.W., Kirkpatrick B., Lann H.D., Breier A.F., Summerfelt A.T. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am. J. Psychiatry 1999, 156(3):412-418.
7. Chen E.Y., Hui C.L., Lam M.M., Chiu C.P., Law C.W., Chung D.W., Tso S., Pang E.P., Chan K.T., Wong Y.C., Mo F.Y., Chan K.P., Yao T.J., Hung S.F., Honer W.G. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ 2010, 341:c4024. 19.
8. Cookson I.B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int. Clin. Psychopharmacol. 1987, 2:141-149.
9. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003, 64(Suppl 12):2-97. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.
10. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J. Biol. Psychiatry 2006, 7:5-40. WFSBP Task Force on Treatment Guidelines for Schizophrenia.
11. Faraone S.V., Green A.I., Brown W., Yin P., Tsuang M.T. Neuroleptic dose reduction in persistently psychotic patients. Hosp. Community Psychiatry 1989, 40:1193-1195.
12. Gaebel W., Weinmann S., Sartorius N., Rutz W., McIntyre J.S. Schizophrenia practice guidelines: international survey and comparison. Br. J. Psychiatry 2005, 187:248-255.
13. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J. Clin. Psychiatry 2011, 72(2):205-218. German Study Group on First-Episode Schizophrenia.
14. Gharabawi G.M., Gearhart N.C., Lasser R.A., Mahmoud R.A., Zhu Y., Mannaert E., Naessens I., Bossie C.A., Kujawa M., Simpson G.M. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann. Gen. Psychiatry 2007, 29(6):3.
15. Haddad P.M., Sharma S.G. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007, 21:911-936.
16. Herz M.I., Glazer W.M., Mostert M.A., Sheard M.A., Szymanski H.V., Hafez H., Mirza M., Vana J. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch. Gen. Psychiatry 1991, 48(4):333-339.
17. Hogarty G.E., Mcevoy J.P., Munetz M., Dibarry A.L., Bartone P., Cather R., Cooley S.J., Ulrich R.F., Carter M., Madonia M.J. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch. Gen. Psychiatry 1988, 45:797-805.
18. Inderbitzin L.B., Lewine R.R., Scheller-Gilkey G., Swofford C.D., Egan G.J., Gloersen B.A., Vidanagama B.P., Waternaux C. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am. J. Psychiatry 1994, 151:1753-1759.
19. International Psychopharmacology Algorithm Project Schizophrenia Algorithm http://www.ipap.org/pdf/schiz/IPAP_Schiz_nodenotes.pdf.
20. Johnson D.A., Ludlow J.M., Street K., Taylor R.D. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br. J. Psychiatry 1987, 151:634-638.
21. Jolley A.G., Hirsch S.R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990, 301(6756):837-842. 13.
22. Kane J.M., Rifkin A., Woerner M., Reardon G., Sarantakos S., Schiebel D., Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch. Gen. Psychiatry 1983, 40:893-896.
23. Kawai N., Yamakawa Y., Baba A., Nemoto K., Tachikawa H., Hori T., Asada T., Iidaka T. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1009-1014.
24. Kreisman D., Blumenthal R., Borenstein M., Woerner M., Kane J., Rifkin A., Reardon G. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. Psychiatry 1988, 51:3-13.
25. Leblanc G., Cormier H., Gagne M.A., Vaillancourt S. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Can. J. Psychiatry 1994, 39:223-229.
26. Lehman A.F., Lieberman J.A., Dixon L.B., Mcglashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161(Suppl):1-56.
27. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 2003, 160:1209-1222.
28. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447.
29. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
30. Leucht S., Heres S., Kissling W., Davis J.M. Evidence-based pharmacotherapy of schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14:269-284.
31. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., Kane J.M., Lieberman J., Schooler N.R. The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. 2002, 28:5-16.
32. Ministry of Health (Singapore) Clinical Practice Guidelines http://www.moh.gov.sg/mohcorp/publications.aspx?id=26138.
33. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 2006, 114:3-13.
34. Moore T.A. Schizophrenia treatment guidelines in the United States. Clin. Schizophr. Relat. Psychoses 2011, 5(1):40-49.
35. National Institute for Health and Clinical Excellence Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) http://guidance.nice.org.uk/CG82/NICEGuidance/pdf/English.
36. Olfson M., Marcus S.C., Corey-Lisle P., Tuomari A.V., Hines P., L'italien G.J. Hyperlipidemia following treatment with antipsychotic medications. Am. J. Psychiatry 2006, 163:1821-1825.
37. Parker C., Coupland C., Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010, 341:c4245. 21. 10.1136/bmj.c4245.
38. Remington G., Seeman P., Shammi C., Mann S., Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J. Clin. Psychopharmacol. 2005, 25(6):611-613.
39. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(8):1042-1048.
40. Rouillon F., Chartier F., Gasquet I. Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study. Eur. Neuropsychopharmacol. 2008, 18:646-652.
41. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust. N. Z. J. Psychiatry 2005, 39:1-30. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders.
42. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., Hargreaves W.A., Kane J.M., Ninan P.T., Frances A., Jacobs M., Lieberman J.A., Mance R., Simpson G.M., Woerner M.G. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psychiatry 1997, 54(5):453-463.
43. Silvestri S., Seeman M.V., Negrete J.C., Houle S., Shammi C.M., Remington G.J., Kapur S., Zipursky R.B., Wilson A.A., Christensen B.K., Seeman P. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2008, 152:174-180.
44. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192:406-411.
45. Suzuki T., Uchida H., Tanaka K.F., Tomita M., Tsunoda K., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G., Kashima H. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int. Clin. Psychopharmacol. 2003, 18:323-329.
46. Suzuki T., Uchida H., Takeuchi H., Nomura K., Tanabe A., Watanabe K., Yagi G., Kashima H. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl) 2005, 181:566-575.
47. Takeuchi H., Suzuki T., Uchida H., Kikuchi T., Nakajima S., Manki H., Watanabe K., Kashima H. How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. J. Psychiatr. Res. 2011, 45:1083-1088.
48. Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines 2009, Informa Healthcare, London. Tenth Edition.
49. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011, 168:603-639.
50. Uchida H., Mamo D.C., Kapur S., Labelle A., Shammi C., Mannaert E.J., Mann S.W., Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry 2008, 69:1281-1286.
51. Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr. Bull. 2009, 37:788-799.
52. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70(Suppl. 4):1-46. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness.
53. Volavka J., Cooper T.B., Czobor P., Lindenmayer J.P., Citrome L.L., Mohr P., Bark N. High-dose treatment with haloperidol: the effect of dose reduction. J. Clin. Psychopharmacol. 2000, 20:252-256.
54. Wang C.Y., Xiang Y.T., Cai Z.J., Weng Y.Z., Bo Q.J., Zhao J.P., Liu T.Q., Wang G.H., Weng S.M., Zhang H.Y., Chen D.F., Tang W.K., Ungvari G.S. For the Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am. J. Psychiatry 2010, 167:676-685.
55. Weinmann S., Hoerger S., Erath M., Kilian R., Gaebel W., Becker T. Implementation of a schizophrenia practice guideline: clinical results. J. Clin. Psychiatry 2008, 69(8):1299-1306.